# Advances in the prevention and prenatal treatment of spina bifida

**Authors:** Zachary B. Sluzala, Katrina E. Furth

PMC · DOI: 10.15190/d.2026.1 · Discoveries · 2026-03-02

## TL;DR

This review discusses recent advances in preventing and treating spina bifida, focusing on prenatal interventions and improved outcomes for patients.

## Contribution

The paper highlights innovative prenatal surgical techniques and emerging therapies like stem cells and 3D printing for spina bifida.

## Key findings

- Folic acid supplementation has significantly reduced new spina bifida cases.
- In-utero surgical techniques are evolving with hybrid open and minimally invasive methods.
- Emerging technologies like stem cell therapy and 3D printing are redefining treatment goals.

## Abstract

Spina bifida is a neural tube defect (NTD) that arises when the neural tube fails to close properly during early development. This review focuses on myelomeningocele (MMC), the most common severe form of spina bifida, which often leads to motor and sensory impairments, including lower limb weakness or paralysis, as well as renal, urological, orthopedic, developmental, and psychosocial challenges. We explore the etiology, pathogenesis, prevention, diagnosis, and management of spina bifida, with a special emphasis on in-utero surgical repair. Over the past several decades, researchers and clinicians have made remarkable strides across all stages of care from prevention to postnatal outcomes. Widespread use of folic acid supplementation has significantly reduced the number of new cases. Advances in prenatal imaging and diagnostics now allow for earlier and more accurate detection, enabling timely intervention. In-utero surgical techniques continue to evolve, with innovative hybrid approaches that combine the strengths of open and minimally invasive methods. The momentum in this field shows no sign of slowing. Promising developments in stem cell therapy, biomaterials, robotic-assisted surgery, 3D printing, and enhanced imaging are redefining treatment goals in spina bifida. With each advance, clinicians gain better tools to improve outcomes for both mother and child, minimizing risks and maximizing long-term health and quality of life for both patients.

## Linked entities

- **Chemicals:** folic acid (PubChem CID 135398658)
- **Diseases:** spina bifida (MONDO:0008449), neural tube defect (MONDO:0018075), myelomeningocele (MONDO:0017069)

## Full-text entities

- **Diseases:** prematurity (MESH:C536271), Neonatal complication (MESH:D007232), membrane separation (MESH:D015433), uterine dehiscence (MESH:D014591), stillbirth (MESH:D050497), congenital condition (MESH:D002908), sepsis (MESH:D018805), cyst (MESH:D003560), psychomotor development (MESH:D002658), incontinence (MESH:D014549), hydrocephalus (MESH:D006849), herniation (MESH:D004677), neurological injury (MESH:D020196), death (MESH:D003643), birth defects (MESH:D000014), hip dislocations (MESH:D006617), scoliosis (MESH:D012600), Spina Bifida (MESH:D016135), syringomyelia (MESH:D013595), loss of sensation (MESH:D006987), premature rupture of membranes (MESH:D005322), urinary tract infection (MESH:D014552), premature birth (MESH:D047928), infections (MESH:D007239), fetal abnormalities (MESH:D005315), clubfoot (MESH:D003025), paralysis (MESH:D010243), kyphosis (MESH:D007738), gestational diabetes (MESH:D016640), Folic acid deficiency (MESH:D005494), CSF leakage (MESH:D065634), bradycardia (MESH:D001919), placental abruption (MESH:D000037), respiratory distress syndrome (MESH:D012128), Chiari II malformation (MESH:D001139), spinal cord cysts (MESH:D013118), neurological deficits (MESH:D009461), spinal defects (MESH:D013122), motor and sensory impairments (MESH:D015417), PPROM (MESH:C563032), NTD (MESH:D009436), seizures (MESH:D012640), shunts (MESH:C562451), dehiscence (MESH:D013529), skin dehiscence (MESH:D012871), uterine rupture (MESH:D014597), CSF (MESH:D002559), congenital anomalies (MESH:D000013), oligohydramnios (MESH:D016104), Complications (MESH:D008107), edema (MESH:D004487), MMC (MESH:D008591), maternal pulmonary edema (MESH:D011654), preeclampsia (MESH:D011225), lower limb weakness (MESH:D018908), rupture (MESH:D012421), leg-length discrepancy (MESH:D007870), bladder muscle overactivity (MESH:D053201)
- **Chemicals:** polypropylene (MESH:D011126), carbon dioxide (MESH:D002245), Folic Acid (MESH:D005492), cellulose (MESH:D002482), CHOP (-), polyethylene (MESH:D020959), silicone (MESH:D012828)
- **Species:** Oryctolagus cuniculus (domestic rabbit, species) [taxon 9986], Homo sapiens (human, species) [taxon 9606], Rattus norvegicus (brown rat, species) [taxon 10116], Ovis aries (domestic sheep, species) [taxon 9940], Sus scrofa (pig, species) [taxon 9823], Mus musculus (house mouse, species) [taxon 10090]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12967227/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12967227/full.md

## References

210 references — full list in the complete paper: https://tomesphere.com/paper/PMC12967227/full.md

---
Source: https://tomesphere.com/paper/PMC12967227